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J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C,ETTER TO THE EDITOR
lucose—insulin—potassium infusion in the man-
gement of acute hyperglycemia in patients with
T-segment elevation acute myocardial infarc-
ion: Lessons learned from randomized trials
o the Editor,
In their recently published article, Nakamura et
l. [1] aimed to evaluate the relationship between
he glucose level and clinical variables during
rimary intervention in patients with ST-elevation
cute myocardial infarction (STEMI). They found
hat corrected thrombolysis in myocardial infarc-
ion (TIMI) frame counts were signiﬁcantly higher
ompared with those in patients without acute
yperglycemia and corrected TIMI frame count
as independently associated with plasma glu-
ose level in patients with acute hyperglycemia.
aximum level of creatine kinase (CK) and CK-MB
ere signiﬁcantly higher in patients with acute
yperglycemia. They concluded that the presence
f acute hyperglycemia was associated with the
mpairment of epicardial coronary ﬂow after
rimary stent implantation.
Although glucose—insulin—potassium (GIK) was
ssociated with a reduction in 1-year mortality in
iabetics with acute myocardial infarction (AMI)
nd elevated glucose, the results in nondiabetics
ith AMI and hyperglycemia have resulted in
omplete disappointment [2—4]. In impact of
lucose—insulin—potassium on mortality and mor-
idity in over 20,000 patients with acute myocardial
nfarction: The CREATE-ECLA International Trial
CREATE-ECLA - GIK) trial, among patients with
MI, treatment with a high-dose GIK infusion
as not associated with a difference in mortality
ompared with controls. The only positive efﬁcacy
nalysis was the association of GIK with a reduction
n recurrent ischemia, although this was not a pri-
ary or secondary endpoint [5]. In Infarct Size and
ortality After Glucose—Insulin—Potassium Infusionn Primary Angioplasty for Acute Myocardial Infarc-
ion trial, among patients with AMI undergoing
rimary angioplasty, treatment with GIK infusion
as associated with a reduction in the frequency
914-5087/$ — see front matter © 2009 Japanese College of Cardiolof the highest quartile of enzyme release, but
as not associated with a difference in 30-day
ortality in the total study population [6]. The
ombined OASIS-6 and CREATE-ECLA trial analysis
f almost 23,000 patients with STEMI (the largest
lobal experience with GIK therapy) demonstrates
hat GIK infusion has no effect on any important
linical endpoint through 30 days following STEMI.
oreover, GIK therapy appears to initially increase
he rate of death postinfarction, and this may
e due to its propensity to increase glucose and
otassium levels and net ﬂuid gain. Early adminis-
ration of GIK therapy (within 4 h) after symptom
nset does not appear to have beneﬁt compared
ith later initiation of GIK therapy [7]. Lastly, in
lucose—Insulin—Potassium Study in Patients with
T Elevation Myocardial Infarction Without Signs of
eart Failure (GIPS II) study, among patients with
TEMI without signs of heart failure, treatment
ith high-dose GIK in addition to standard therapy
as not associated with a reduction in 30-day
ortality compared with standard therapy [8].
In conclusion, although hyperglycemia during
MI is associated with worse short- and long-
erm cardiovascular outcomes, whether control of
lycemia is sufﬁcient to reduce morbidity and mor-
ality is not proven at the present time. More
mportantly, target glucose levels in patients with
MI has not been clearly deﬁned. I strongly believe
hat major outcome studies are warranted to deﬁne
ptimal glucose concentrations in patients present-
ng with AMI.
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In our study, we evaluated the relationship
between the glucose levels on admission and
the angiographic ﬁndings during primary stent
implantation in patients with ST-elevation acute
myocardial infarction (STEMI). We did not inves-
tigate the effect of insulin therapy, therefore we
could not conclude whether tight control of glu-
cose levels is sufﬁcient to improve the prognosis
in patients with STEMI. Indeed, some clinical tri-
als failed to evaluate the efﬁcacy of GIK therapy. dLetters to the Editor
owever, there are some important problems in
hese trials. First, most of subjects in these tri-
ls were treated by thrombolytic therapy. In the
REATE-ECLA trial, primary coronary intervention
as performed in only 9% of all subjects [1]. More-
ver, the glucose levels 24 h after randomization in
he GIK treatment group were higher than in the
ontrol group in the combined OASIS-6 and CREATE-
CLA trial analysis (155mg/dl vs 135mg/dl) [2].
yperglycemia and hyperinsulinemia lead to pro-
oagulant and pro-inﬂammatory states. In the GIPS
I study, blood glucose levels after randomization
ere not recorded [3]. We think that the aim of
nsulin therapy in STEMI is to normalize the glucose
evel, not to infuse the insulin—glucose—potassium.
ecently, Kosiborod et al. [4] have reported that
lucose normalization after admission is associated
ith better survival in hyperglycemic patients with
MI whether or not they receive insulin therapy. And
hey have suggested that the in-hospital mortality
ate increased according to the elevation of glucose
evel above the threshold of 130mg/dl.
We also hope that large, randomized clinical
rials are warranted to deﬁne the optimal target
lucose level in patients with STEMI.
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